Evidence map›Paper›PMID 41728096›Full record

ArticleGlobal advances in integrative medicine and health

Efficacy of Jiinshihoto on Depressive Symptoms in Patients With Pulmonary

Makiko Yamaguchi, Keiko Ogawa-Ochiai, Tadashi Toyama, Kosuke Kurokawa, Toshihiro Takeda, Masayuki Sato, Miho Mitsui, Akikazu Shimada, Tomoaki Sonoda, Chisato Honjo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global advances in integrative medicine and health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Makiko YamaguchiDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.ORCID https://orcid.org/0000-0003-4553-7330
Keiko Ogawa-OchiaiKampo Clinical Center, Hiroshima University Hospital, Hiroshima, Japan.ORCID https://orcid.org/0000-0002-3277-0646
Tadashi ToyamaDepartment of Nephrology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Kosuke KurokawaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Toshihiro TakedaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Masayuki SatoDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Miho MitsuiDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Akikazu ShimadaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Tomoaki SonodaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Chisato HonjoDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Maiko KadowakiDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Yukihiro UmedaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Tamotsu IshizukaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
Yuko WasedaDepartment of Respiratory Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.ORCID https://orcid.org/0000-0002-7120-8517

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with pulmonary Objective: To evaluate the physical, immunological, and psychiatric effects of Jiinshihoto in patients with pulmonary MAC who were ineligible for standard antimicrobial treatment. Methods: This single-center, open-label, prospective study was conducted from March 2018 to January 2020. Patients who were not eligible for standard treatment for pulmonary MAC disease were enrolled. Jiinshihoto (3.0 g) was administered three times per day for 12 months. The primary endpoints were 3-month changes in chronic obstructive pulmonary disease assessment test (CAT) scores, body weight, and natural killer (NK) cell activity. Secondary endpoints were 3-month changes in self-rating depression scale (SDS) scores. This study was registered in the UMIN-Clinical Trials Registry (UMIN000033590). Results: In total, 24 patients were enrolled. The mean age was 68 years, and 74% were female; the mean body mass index was 19.3 kg/m Conclusion: Jiinshihoto did not improve respiratory symptoms, weight, or NK cell activity in patients with pulmonary MAC ineligible for standard treatment but may be beneficial for depressive symptoms.

Indexed as

body mass indexdepressionJiinshihotoMycobacterium avium complexnatural killer cell activity

Identifiers

PMID41728096
PMCPMC12921178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.